EIMindA’s BNA Analysis System Receives FDA Approval

August 6, 2014 | Israeli brain research company EIMindA announced that the United States Food & Drug Administration (FDA) has cleared the company’s BNA Analysis System for the assessment of brain function. The Brain Network Activity combines non-invasive, multi-channel EEG technology with signal processing and analysis algorithms to assess brain activity during certain processes. The system is then able to take the data it collects and provide both quantitative and qualitative insights into brain functionality. “Greater understanding of how our brain processes information, how it gets its job done, ultimately holds the potential to improve brain health and disease management over a person’s lifetime,” said Ronen Gadot, CEO of EIMindA. EIMindA was founded in 2006 to address an unmet need in the accurate, objective diagnosis and treatment of brain-related disorders through a data-driven approach.